Johnson Johnson AbbVie: Paths to Pharma Dominance
Johnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Index investing lowers risk by reducing idiosyncratic bets and fees, delivering steadier, long-term growth. This intro explains the rationale and steps.
27,508 articlesJohnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
JPMorgan Chief Executive Jamie Dimon hints at a post-CEO second act that could include writing, teaching, and media p...
Roth IRAs are popular for tax-free growth, but they’re not the perfect fit for everyone. Here are three practical rea...
Redfin signals a housing market reset beginning in 2026. This article breaks down what that could mean for loans, buy...
Gary Keller argues that a data-driven view can outweigh market gloom, foreseeing 4.3 million home sales in 2026 and a...
Block reveals a sweeping AI-focused restructuring, trimming about 40% of its workforce and triggering a strong after-...
As markets navigate a choppy start to March 2026, traders rely on the best stock scanners screeners to turn vast data...
Oil clears $100 a barrel, sending Exxon and Chevron higher in after-hours trading while Berkshire Hathaway retreats a...
Airbnb announced a $2.5 billion bond offering, sending ABNB shares down about 4% as investors weigh a shift in the co...
A gripping court filing alleges a spouse exploited surveillance and a seed phrase to drain a vast Bitcoin stash. This...
LyondellBasell shares have surged about 74% year-to-date, trading near $75 as of mid-March 2026. The rally comes desp...
Markets react to renewed chatter that spacex could soon file for a historic IPO, potentially reshaping space equities...